Epigenetics and the Environment: In Search of the "Toleroasome" Vital to Execution of Ischemic Preconditioning

Translational Stroke Research

Volumn 4, Issue 1, 2013, Pages 56-62

  Brand, David ^a,b,c   Ratan, Rajiv R ^b,c  

^a AMHERST COLLEGE   (United States)

^b Burke Cornell Medical Research Institute   (United States)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Epigenetics; Histone deacetylase; Histone demethylase; Ischemic preconditioning; Polycomb

Indexed keywords

2 OXOGLUTARIC ACID; ADENOSINE TRIPHOSPHATE; ADENYLATE KINASE; HISTONE DEMETHYLASE; NICOTINAMIDE ADENINE DINUCLEOTIDE; OXYGEN; POLYCOMB GROUP PROTEIN; SIRTUIN;

COMPLEX FORMATION; DEMETHYLATION; ENVIRONMENTAL FACTOR; EPIGENETICS; GENOMICS; HUMAN; ISCHEMIC PRECONDITIONING; MOLECULAR MECHANICS; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN MODIFICATION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; REVIEW;

BRAIN; BRAIN ISCHEMIA; EPIGENESIS, GENETIC; HISTONE DEMETHYLASES; HUMANS; ISCHEMIC PRECONDITIONING; JUMONJI DOMAIN-CONTAINING HISTONE DEMETHYLASES; POLYCOMB-GROUP PROTEINS;

EID: 84872647971     PISSN: 18684483     EISSN: 1868601X     Source Type: Journal    
DOI: 10.1007/s12975-012-0235-0     Document Type: Review

References (58)

1. Abel T, Zukin RS. Epigenetic targets of HDAC inhibition in neurodegenerative and psychiatric disorders. Curr Opin Pharmacol. 2008; 8(1): 57-64.
2. Baltan S, et al. Expression of histone deacetylases in cellular compartments of the mouse brain and the effects of ischemia. Transl Stroke Res. 2011; 2(3): 411-23.
3. Baltan S, et al. Histone deacetylase inhibitors preserve white matter structure and function during ischemia by conserving ATP and reducing excitotoxicity. J Neurosci. 2011; 31(11): 3990-9.
4. Baranova O, et al. Neuron-specific inactivation of the hypoxia inducible factor 1 alpha increases brain injury in a mouse model of transient focal cerebral ischemia. J Neurosci. 2007; 27(23): 6320-32.
5. Bradner JE, et al. Chemical phylogenetics of histone deacetylases. Nat Chem Biol. 2010; 6(3): 238-43.
6. Bungard D, et al. Signaling kinase AMPK activates stress-promoted transcription via histone H2B phosphorylation. Science. 2010; 329(5996): 1201-5.
7. Chandra P, Wright GJ. Tilorone hydrochloride: the drug profile. Top Curr Chem. 1977; 72: 125-48.
8. Chuang DM, et al. Multiple roles of HDAC inhibition in neurodegenerative conditions. Trends Neurosci. 2009; 32(11): 591-601.
9. Chavez JC, LaManna JC. Activation of hypoxia-inducible factor-1 in the rat cerebral cortex after transient global ischemia: potential role of insulin-like growth factor-1. J Neurosci. 2002; 22(20): 8922-31.
10. Dioum EM, et al. Regulation of hypoxia-inducible factor 2alpha signaling by the stress-responsive deacetylase sirtuin 1. Science. 2009; 324(5932): 1289-93.
11. Elkins JM, et al. Structure of factor-inhibiting hypoxia-inducible factor (HIF) reveals mechanism of oxidative modification of HIF1 alpha. J Biol Chem. 2003; 278(3): 1802-6.
12. Gidday JM. Cerebral preconditioning and ischaemic tolerance. Nat Rev Neurosci. 2006; 7(6): 437-48.
13. He W, et al. Mitochondrial sirtuins: regulators of protein acylation and metabolism. Trends Endocrinol Metab. 2012; 23(9): 467-76.
14. Karuppagounder SS, Ratan RR. Hypoxia-inducible factor prolyl hydroxylase inhibition: robust new target or another big bust for stroke therapeutics? J Cereb Blood Flow Metab. 2012; 32(7): 1347-61.
15. Kazantsev A, Thompson LM. Therapeutic application of histone deacetylase inhibitors for central nervous system disorders. Nat Rev Drug Discov. 2008; 7(10): 854-68.
16. Kim JY, et al. HDAC1 nuclear export induced by pathological conditions is essential for the onset of axonal damage. Nat Neurosci. 2010; 13(2): 180-9.
17. Klose RJ, et al. JmjC-domain-containing proteins and histone demethylation. Nat Rev Genet. 2006; 7(9): 715-27.
18. Krieg AJ, et al. Regulation of the histone demethylase JMJD1A by hypoxia-inducible factor 1 alpha enhances hypoxic gene expression and tumor growth. Mol Cell Biol. 2010; 30(1): 344-53.
19. waf1/cip1 in cell cycle-independent neuroprotection. J Neurosci. 2008; 28(1): 163-76.
20. Lanzuolo C, Orlando V. Memories from the polycomb group proteins. Annu Rev Genet. 2012; 46: 561-89.
21. Lee YJ, et al. SUMOylation participates in induction of ischemic tolerance. J Neurochem. 2009; 109(1): 257-67.
22. Lee YJ, et al. Elevated global SUMOylation in Ubc9 transgenic mice protects their brains against focal cerebral ischemic damage. PLoS One. 2011; 6(10): e25852.
23. Li J, et al. Nuclear accumulation of HDAC4 in ATM deficiency promotes neurodegeneration in ataxia telangiectasia. Nat Med. 2012; 18(5): 783-90.
24. McCullough LD, et al. Pharmacological inhibition of AMP-activated protein kinase provides neuroprotection in stroke. J Biol Chem. 2005; 280(21): 20493-502.
25. Menino AM, et al. Deaths: final data for 2008. Natl Natl Vital Stat Rep. 2011; 59(10): 1-126.
26. Morris KC, et al. Pathways for ischemic cytoprotection: role of sirtuins in caloric restriction, resveratrol, and ischemic preconditioning. J Cereb Blood Flow Metab. 2011; 31(4): 1003-19.
27. Mosammaparast N, Shi Y. Reversal of histone methylation: biochemical and molecular mechanisms of histone demethylases. Annu Rev Biochem. 2010; 79: 155-79.
28. Nogueiras R, et al. Sirtuin 1 and sirtuin 3: physiological modulators of metabolism. Physiol Rev. 2012; 92(3): 1479-514.
29. Pamenter ME, et al. Painted turtle cortex is resistant to an in vitro mimic of the ischemic mammalian penumbra. J Cereb Blood Flow Metab. 2012. doi: 10. 1038/jcbfm. 2012. 103.
30. Qureshi IA, Mehler MF. The emerging role of epigenetics in stroke: II. RNA regulatory circuitry. Arch Neurol. 2010; 67(12): 1435-41.
31. Ramamurthy S, Ronnett G. AMP-activated protein kinase (AMPK) and energy-sensing in the brain. Exp Neurobiol. 2012; 21(2): 52-60.
32. Rane S, et al. Downregulation of miR-199a derepresses hypoxia-inducible factor-1alpha and sirtuin 1 and recapitulates hypoxia preconditioning in cardiac myocytes. Circ Res. 2009; 104(7): 879-86.
33. Ratan RR. Epigenetics and the nervous system: epiphenomenon or missing piece of the neurotherapeutic puzzle? Lancet Neurol. 2009; 8(11): 975-7.
34. Ratan RR, et al. Small molecule activation of adaptive gene expression: tilorone or its analogs are novel potent activators of hypoxia inducible factor-1 that provide prophylaxis against stroke and spinal cord injury. Ann N Y Acad Sci. 2008; 1147: 383-94.
35. Raval AP, et al. Resveratrol and ischemic preconditioning in the brain. Curr Med Chem. 2008; 15(15): 1545-51.
36. Raval AP, et al. Resveratrol mimics ischemic preconditioning in the brain. J Cereb Blood Flow Metab. 2006; 26(9): 1141-7.
37. Riccio A. New endogenous regulators of class I histone deacetylases. Sci Signal. 2010; 3(103): pe1.
38. Ryu H, et al. Histone deacetylase inhibitors prevent oxidative neuronal death independent of expanded polyglutamine repeats via an Sp1-dependent pathway. Proc Natl Acad Sci U S A. 2003; 100(7): 4281-6.
39. Savitz SI, Fisher M. Future of neuroprotection for acute stroke: in the aftermath of the SAINT trials. Ann Neurol. 2007; 61(5): 396-402.
40. Sharp FR, et al. Hypoxic preconditioning protects against ischemic brain injury. NeuroRx. 2004; 1(1): 26-35.
41. Simon RP. Can genes modify stroke outcome and by what mechanisms? Stroke. 2012; 43(1): 286-91.
42. Sleiman SF, et al. Putting the 'HAT' back on survival signalling: the promises and challenges of HDAC inhibition in the treatment of neurological conditions. Expert Opin Investig Drugs. 2009; 18(5): 573-84.
43. Stapels M, et al. PcG as epigenetic mediators of neuroprotection in ischemic tolerance. Sci Signal. 2010; 3(111): ra15 1-11.
44. Stenzel-Poore MP, et al. Effect of ischemic preconditioning on genomic response to cerebral ischemia: similarity to neuroprotective strategies in hibernation and hypoxia-tolerant states. Lancet. 2003; 362: 1028-37.
45. Stevens SL, et al. Multiple preconditioning paradigms converge on interferon regulatory factor-dependent signaling to promote tolerance to ischemic brain injury. J Neurosci. 2011; 31(23): 8456-63.
46. Takeuchi T, et al. Roles of jumonji and jumonji family genes in chromatin regulation and development. Dev Dyn. 2006; 235(9): 2449-59.
47. Taverna SD, et al. How chromatin-binding modules interpret histone modifications: lessons from professional pocket pickers. Nat Struct Mol Biol. 2007; 14(11): 1025-40.
48. Tsukada Y, et al. Histone demethylation by a family of JmjC domain-containing proteins. Nature. 2006; 439(7078): 811-6.
49. Uo T, et al. Histone deacetylase inhibitors prevent p53-dependent and p53-independent Bax-mediated neuronal apoptosis through two distinct mechanisms. J Neurosci. 2009; 29(9): 2824-32.
50. Wang T, et al. The histone demethylases Jhdm1a/1b enhance somatic cell reprogramming in a vitamin-C-dependent manner. Cell Stem Cell. 2011; 9(6): 575-87.
51. Yildirim F, et al. Inhibition of histone deacetylation protects wildtype but not gelsolin-deficient mice from ischemic brain injury. Exp Neurol. 2008; 210(2): 531-42.
52. Zeynalov E, Shah ZA, Li RC, Doré S. Heme oxygenase 1 is associated with ischemic preconditioning-induced protection against brain ischemia. Neurobiol Dis. 2009; 35(2): 264-9. Epub 2009 May 22.
53. Zukin RS. Eradicating the mediators of neuronal death with a fine-tooth comb. Sci Signal. 2010; 3(125): pe20.
54. Zhou Y, Fathali N, Lekic T, Ostrowski RP, Chen C, Martin RD, Tang J, Zhang JH. Remote limb ischemic postconditioning protects against neonatal hypoxic-ischemic brain injury in rat pups by the opioid receptor/Akt pathway. Stroke. 2011; 42(2): 439-44.
55. Cheng O, Ostrowski RP, Wu B, Liu W, Chen C, Zhang JH. Cyclooxygenase-2 mediates hyperbaric oxygen preconditioning in the rat model of transient global cerebral ischemia, Stroke. 2011; 42(2): 484-90.
56. Rivieccio MA, Brochier C, Willis DE, Walker BA, D'Annibale MA, McLaughlin K, et al. HDAC6 is a target for protection and regeneration following injury in the nervous system, Proc. Natl. Acad. Sci. U. S. A. 2009; 106: 19599-19604.
57. Munirathinam G, Ramaswamy K. Sumoylation of human translationally controlled tumor protein is important for its nuclear transport, Biochem Res Int. 2012.
58. McConoughey SJ, et al. Inhibition of transglutaminase 2 mitigates transcriptional dysregulation in models of Huntington disease. EMBO Mol. Med. 2010; 2(9): 349-370.